Clinical Trials | December 07, 2025
Bayer reports promising results for low-dose pediatric MRI contrast agent
MRI is particularly valuable in pediatric care due to its non-invasive nature
MRI is particularly valuable in pediatric care due to its non-invasive nature
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Millions of stroke survivors across the world may soon have a new defense
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New study presents a human-relevant stress model for assessing potential therapeutics
The lab will facilitate the development of herbal and natural-based solutions
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Subscribe To Our Newsletter & Stay Updated
